FDA approves new drug to treat tuberculosis
Tuberculosis kills nearly 1.4 million people in the world each year
 |
| new,drug,Stem cells,Multiple Sclerosis,Ms,Health,Medicine,Disease,الخلايا الجذعيه,الصحه,الطب,الامراض,التصلب المتعدد |
Approved US FDA this week on the first drug for treatment of tuberculosis (TB) for the first time in 40 years.
The
Commission has agreed on a Sirturo produced by the Johnson and Johnson
company to be dealt with at the old property to combat the strain of
tuberculosis is difficult to treat and does not respond to other drugs,
but they returned to warn the deadly health risks caused by the new
heart drug, stressing the need for caution when describing the new
property.
Overall,
approximately one third of the world's people are infected with TB
bacteria, although the disease is rare in the United States that caused
the death of nearly 1.4 million people worldwide each year, about
150,000 of them are kind of disease resistant to conventional drugs.
And about 60 percent of the cases in China and India, Russia and Eastern Europe.
And
property Sirturo bedaquiline what is known as the first drug designed
specifically for dealing with drug-resistant tuberculosis, is a kind of
disease that cannot be treated with at least two of the four antibiotics
prescribed as a treatment for tuberculosis and produced in the 50s of
the last century services.
Crispin
kambili said from the manufacturer "these antibiotics are traded for
treatment of the disease for more than 40 years, this has become
pathogenic bacteria more resistant."
Medical
bulletin contains new drug warning of its potential impact on
electrical activity of the heart, may lead to serious heart rhythm.
"Edward
Cox, Director of the Bureau of anti-bacteria with the US FDA that"
Sirturo discs provide needed treatment for patients who have no other
option to cure the disease, doctors must ensure that well that is
appropriately addressed because it carries significant risks for heart
patients who do not work with them any property. "
ليست هناك تعليقات:
إرسال تعليق